Patients with higher-grade chronic kidney disease (CKD) but no established cardiovascular disease who took daily aspirin showed a significant 43% cut in the rate of adverse cardiovascular events with no increase in bleeding, compared with placebo during a median 4.6 years of follow-up.
The finding appears to identify a high-risk population — people with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1. 73m2 who averaged 67 years old — that bucks the now established advice to not start low-dose aspirin for primary prevention of cardiovascular disease events in people older than 59 years
